Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Rev Mal Respir ; 36(6): 649-663, 2019 Jun.
Artigo em Francês | MEDLINE | ID: mdl-31204231

RESUMO

INTRODUCTION: The benefit of tyrosine kinase inhibitors for patients with an EGFR wild-type non-small cell lung cancer (NSCLC) remains controversial. METHODS: The survival of patients with an EGFR wild-type NSCLC who received second- or third-line erlotinib treatment was assessed using real-life data that had been collected in a prospective, national, multicenter, non-interventional cohort study. RESULTS: Data from 274 patients were analysed, 185 (68%) treated with erlotinib and 89 (32%) treated with supportive care only. The median overall survival was 4.2months (95% CI [3.5; 5.4]) with erlotinib, and 1.3months (95% CI [1.0; 1.8]) with supportive care. Survival rate at 3, 6, and 12months was 62%, 37%, and 17%, respectively, with erlotinib, versus 20%, 8%, et 3%, with exclusive supportive care. Significant predictive factors for longer overall survival were the presence of adenocarcinoma, and use of 1st line chemotherapy including either taxanes, pemetrexed or vinorelbine (P<0.05). CONCLUSION: Erlotinib remains a valuable therapeutic option to treat inoperable locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen in fragile patients who are not eligible for chemotherapy.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Cloridrato de Erlotinib/uso terapêutico , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/mortalidade , Inibidores de Proteínas Quinases/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Pulmonar de Células não Pequenas/genética , Receptores ErbB/genética , Feminino , Humanos , Neoplasias Pulmonares/genética , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Taxa de Sobrevida
2.
Ann Biol Clin (Paris) ; 66(5): 581-3, 2008.
Artigo em Francês | MEDLINE | ID: mdl-18957351

RESUMO

Aspergillus species are filamentous fungi of Ascomycete class. They are opportunistic pathogens frequently responsible for many severe infections. Among these species Aspergillus fumigatus is the most important human pathogen because of his thermophilic feature. Concerning microscopic morphology Aspergillus fumigatus is characterized by an asexual multiplication with a conidiophore formed by a conical-shaped vesicle. The phialides are directly attached to this clavated vesicle (uniseriate) and produce conidia chains. We report the case of mycological examination identifying a non uniseriate Aspergillus strain which belongs to Fumigati section.


Assuntos
Aspergilose Broncopulmonar Alérgica , Aspergillus fumigatus , Idoso , Antifúngicos/administração & dosagem , Antifúngicos/uso terapêutico , Aspergilose Broncopulmonar Alérgica/complicações , Aspergilose Broncopulmonar Alérgica/diagnóstico , Aspergilose Broncopulmonar Alérgica/tratamento farmacológico , Carcinoma de Células Grandes/complicações , Carcinoma de Células Grandes/patologia , Feminino , Humanos , Itraconazol/administração & dosagem , Itraconazol/uso terapêutico , Pulmão/patologia , Neoplasias Pulmonares/complicações , Neoplasias Pulmonares/patologia , Técnicas de Tipagem Micológica , Estadiamento de Neoplasias , Radiografia Torácica , Tomografia Computadorizada por Raios X , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...